MedPath

Radiation Dose Escalation Study for Advanced Liver Cancer

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Radiation: 3DCRT/IMRT
Registration Number
NCT00848094
Lead Sponsor
Fudan University
Brief Summary

The purpose of this clinical study is to determine the maximum tolerated dose (MTD) of 3-dimensional conformal radiation therapy (3-DCRT)/intensity modulated radiation therapy (IMRT) for locally advanced hepatocellular carcinoma (HCC).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Pathologically confirmed or clinically diagnosed HCC
  • Surgically unsectable or medically inoperable diseases, or surgery declined by the patient
  • Solitary intrahepatic lesion with diameter bigger than 5 cm, without extrahepatic and/or distant metastases
  • Associated with cirrhosis of Child-Pugh A
  • Karnofsky performance status (KPS) of ≥ 70
  • Normal renal function and adequate bone marrow reservation
  • Tolerate active breathing control (ABC)
Exclusion Criteria
  • Child-Pugh B or C liver cirrhosis score
  • Previous radiotherapy to the liver
  • Indistinct tumor boundary in CT/MRI image

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
arm 13DCRT/IMRTArm I: tumor diameter more than 5 cm and less than 10 cm.
arm 23DCRT/IMRTArm II: tumor diameter no less than 10 cm.
Primary Outcome Measures
NameTimeMethod
Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.4 months
Secondary Outcome Measures
NameTimeMethod
1,2 and 3 years survival4 years
© Copyright 2025. All Rights Reserved by MedPath